Literature DB >> 15347895

Weekly paclitaxel combined with local hyperthermia in the therapy of breast cancer locally recurrent after mastectomy--a pilot experience.

Z Zoul1, S Filip, B Melichar, J Dvorák, K Odrázka, J Petera.   

Abstract

BACKGROUND: The combination of chemotherapy and hyperthermia (HT) is a promising approach in the treatment of malignant tumors. In the present report we evaluate the efficacy and toxicity of a combination of weekly paclitaxel combined with local hyperthermia in breast cancer. PATIENTS AND METHODS: 7 patients were treated for inoperable local recurrence of breast cancer after mastectomy, irradiation, and chemotherapy or hormonal therapy. They weekly received paclitaxel (60-80 mg/m(2)) in 3-h infusions followed by local HT 41-44 degrees C for 45 min for 6-18 cycles.
RESULTS: Objective local response was observed in all treated patients (complete response in 4 patients and partial response in 3 patients). There were no grade 3 or 4 toxicities, neurologic toxicity or hypersensitivity reactions. Local tolerance to this regimen was also good, with only 4 patients developing mild transient erythema.
CONCLUSION: Our experience indicates that the combination of weekly paclitaxel and HT may be effective in the treatment of locally recurrent breast cancer after mastectomy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15347895     DOI: 10.1159/000079093

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  2 in total

1.  Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice.

Authors:  Yoshiaki Kanaya; Hiroyoshi Doihara; Kouji Shiroma; Yutaka Ogasawara; Hiroshi Date
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

2.  Sub-lethal hyperthermia promotes epithelial-to-mesenchymal-like transition of breast cancer cells: implication of the synergy between hyperthermia and chemotherapy.

Authors:  Tae Hee Lee; Jiyoon Bu; Byoung Hyuck Kim; Michael J Poellmann; Seungpyo Hong; Sung Hee Hyun
Journal:  RSC Adv       Date:  2018-12-20       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.